Who Paid My Doc
Amar Patel
Foot and Ankle Surgery Lees Summit, MO Medical Doctor
NPI 1841300571 CMS profile 220102
120 Ne Saint Lukes Blvd Ste 200, Lees Summit, MO 64086
General payments
$202,844
Research payments
$0
Ownership & investment interest
$1,181,575
Research they led as principal investigator
$53,500
Through program year 2025, Amar Patel of Lees Summit, MO is reported in the CMS Open Payments database as having received $202,844 across 198 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $53,500 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,181,575 across 9 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
14 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $62,271 | 38 | |
| 2024 | General | $4,389 | 40 | |
| 2023 | General | $29,882 | 26 | |
| 2022 | General | $26,109 | 32 | |
| 2021 | General | $25,897 | 23 | |
| 2020 | General | $26,602 | 18 | |
| 2019 | General | $27,693 | 21 | |
| 2025 | Ownership | $15,383 | 1 | |
| 2024 | Ownership | $15,383 | 1 | |
| 2023 | Ownership | $13,217 | 1 | |
| 2022 | Ownership | $13,217 | 1 | |
| 2021 | Ownership | $10,292 | 1 | |
| 2020 | Ownership | $557,042 | 2 | |
| 2019 | Ownership | $557,042 | 2 |
Beside peers
- Amar Patel
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Amar Patel were reported at $62,271. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Amar Patel | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $27,693 | $1,327 | $279–$5,421 | $163 |
| 2020 | $26,602 | $795 | $121–$3,473 | $114 |
| 2021 | $25,897 | $1,289 | $201–$4,963 | $132 |
| 2022 | $26,109 | $1,539 | $270–$6,067 | $149 |
| 2023 | $29,882 | $1,117 | $257–$5,264 | $160 |
| 2024 | $4,389 | $1,064 | $235–$4,944 | $164 |
| 2025 | $62,271 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
1,645
Drug cost
$24,281
Branded share of claims
14.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 16 | $8,517 | |
| Gabapentin | Generic | 211 | $2,697 | |
| Pregabalin | Generic | 69 | $1,421 | |
| Enoxaparin Sodium | Generic | 16 | $1,354 | |
| Tizanidine Hcl | Generic | 100 | $1,214 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 117 | $1,206 | |
| Celecoxib | Generic | 20 | $1,168 | |
| Oxycodone Hcl | Generic | 166 | $1,098 | |
| Meloxicam | Generic | 561 | $1,034 | |
| Diclofenac Sodium | Generic | 31 | $981 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 153 billing codesPaid by Medicare
$288,541
Medicare patients
521
Services billed
3,658
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 71% | |
| Arthritis | 69% | |
| Depression | 29% | |
| Diabetes | 28% | |
| Ischemic heart disease | 26% | |
| Chronic kidney disease | 22% | |
| Osteoporosis | 20% | |
| Heart failure | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 77 | 354 | $256 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
198 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Missouri
Jeremy McCormick
Foot and Ankle Surgery · Saint Louis, MO
Jeffrey Johnson
Foot and Ankle Surgery · Saint Louis, MO
Timothy Badwey
Foot and Ankle Surgery · Kansas City, MO
Brian Kleiber
Foot and Ankle Surgery · Columbia, MO
Levi Gause
Foot and Ankle Surgery · Columbia, MO
Kelly Hynes
Foot and Ankle Surgery · Saint Louis, MO
Related records
Foot and Ankle Surgery in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.